Sign inCreate account

Report workspace tools

NCT06285643RECRUITINGanonymous

A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults With Moderate Stage Parkinson's Disease

Sponsor

Source record

AskBio Inc

Phase

Source record

Phase 2

Modality

AI-normalized

gene therapy

Target

AI-normalized

AAV2-GDNF gene therapy for Parkinson's Disease

Indication / condition

AI-normalized

Parkinson Disease

Intervention

Source record

AAV2-GDNF gene therapy, control surgery

Source & freshness

Source record

NCT ID

NCT06285643

Original source

ClinicalTrials.gov

Source last updated

Dec 08, 2025

Ingested at

May 31, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06285643

Title

A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults With Moderate Stage Parkinson's Disease

Sponsor

AskBio Inc

Status

RECRUITING

Phase

Phase 2

Condition raw

Parkinson Disease

Condition normalized

Parkinson Disease

Modality raw

Parkinson Disease

Modality normalized

gene therapy

Target raw

AAV2-GDNF gene therapy for Parkinson's Disease

Target normalized

AAV2-GDNF gene therapy for Parkinson's Disease

Interventions

AAV2-GDNF gene therapy, control surgery

Public preview

Source record

AskBio Inc is conducting a Phase 2 clinical trial to evaluate the safety and efficacy of AAV2-GDNF gene therapy in adults with moderate Parkinson's Disease. The trial is randomized, double-blind, and sham-controlled, aiming to enroll approximately 127 participants across multiple sites in the U.S. and Germany.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults With Moderate Stage Parkinson's Disease

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT06285643

Status

RECRUITING

Phase

Phase 2

Sponsor

AskBio Inc

Executive brief

Investment-Ready Snapshot

AskBio Inc is conducting a Phase 2 clinical trial to evaluate the safety and efficacy of AAV2-GDNF gene therapy in adults with moderate Parkinson's Disease. The trial is randomized, double-blind, and sham-controlled, aiming to enroll approximately 127 participants across multiple sites in the U.S. and Germany.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedDec 08, 2025
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06285643

Indication

Parkinson Disease

Modality

gene therapy

Target

AAV2-GDNF gene therapy for Parkinson's Disease

Intervention

AAV2-GDNF gene therapy, control surgery

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.